According to the new research report published by Precedence Research, titled “Cell and Gene Therapy Clinical Trials Market (By Phase: Phase I, Phase II, Phase III, Phase IV; By Indication: Oncology, Cardiology, CNS, Musculoskeletal, Infectious Diseases, Dermatology, Endocrine, Metabolic, Genetic, Immunology & Inflammation, Ophthalmology, Hematology, Gastroenterology, Others) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032 (By Product: Traditional, Advanced; By Application: Pottery, Tiles, Abrasives, Sanitary wave, Bricks & pipes, Others; By End User: Medical, Industrial, Building & Construction, Others) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032”, the global cell and gene therapy clinical trials market size is expected to be worth around US$ 40.98 billion by 2032 and is poised to record a yearly growth rate of 15.09% from 2023 to 2032. The study investigates several elements and their consequences on the growth of the all-wheel drive market.
This report focuses on cell and gene therapy clinical trials market volume and value at the global level, regional level and company level. From a global perspective, this report represents the overall cell and gene therapy clinical trials market size by analysing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, the Middle East & Africa, Latin America, etc.
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2032. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Download a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2881
The study also provides important advancements in organic and inorganic growth strategies in the worldwide cell and gene therapy clinical trials market. A lot of corporations are prioritizing new launches, product approvals, and other business expansion techniques. In addition, the report offers profiles of cell and gene therapy clinical trials market firms and market strategies. Furthermore, the research focuses on top industry participants, providing information such as company profiles, components and services offered, recent financial data, and key developments.
Cell and Gene Therapy Clinical Trials Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 11.57 Billion |
| Market Size by 2032 | USD 40.98 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 15.09% |
| Largest Market | North America |
| Fastest Growing Market | Asia-Pacific |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Phase and By Indication |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
Also read: Autonomous Trucks Market Size US$ 5.36 Billion by 2032
Market Key Players
Company profiles have been included in the report, which include essentials such as product portfolio, key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting market status and predicting the competition level in the cell and gene therapy clinical trials market.
Some of the prominent players in the cell and gene therapy clinical trials market include
- IQVIA
- ICON Plc
- Laboratory Corporation of America Holdings
- Charles River Laboratories International, Inc.
- PAREXEL International Corp.
- Syneos Health
- Medpace Holdings, Inc.
- PPD Inc.
- Novotech
- Veristat, LLC
Cell and Gene Therapy Clinical Trials Market Segmentations
By Phase
- Phase I
- Phase II
- Phase III
- Phase IV
By Indication
- Oncology
- Cardiology
- CNS
- Musculoskeletal
- Infectious Diseases
- Dermatology
- Endocrine, Metabolic, Genetic
- Immunology & Inflammation
- Ophthalmology
- Hematology
- Gastroenterology
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Report Objectives
- To define, segment, and project the global market size for cell and gene therapy clinical trials market
- To understand the structure of the market by identifying its various sub-segments
- To provide detailed information about the key factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
- To analyse the micro-markets, with respect to individual growth trends, future prospects, and their contributions to the total market
- To project the size of the market and its submarkets, in terms of value, with respect to global. (along with their respective key countries)
- To profile key players and comprehensively analyse their core competencies
- To understand the competitive landscape and identify major growth strategies adopted by players across the globe.
- To analyse the competitive developments such as expansions & investments, new product launches, mergers & acquisitions, joint ventures, and agreements
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cell and Gene Therapy Clinical Trials Market
5.1. COVID-19 Landscape: Cell and Gene Therapy Clinical Trials Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cell and Gene Therapy Clinical Trials Market, By Phase
8.1. Cell and Gene Therapy Clinical Trials Market, by Phase, 2023-2032
8.1.1. Phase I
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Phase II
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Phase III
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Phase IV
8.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Cell and Gene Therapy Clinical Trials Market, By Indication
9.1. Cell and Gene Therapy Clinical Trials Market, by Indication, 2023-2032
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Cardiology
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. CNS
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Musculoskeletal
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Infectious Diseases
9.1.5.1. Market Revenue and Forecast (2020-2032)
9.1.6. Dermatology
9.1.6.1. Market Revenue and Forecast (2020-2032)
9.1.7. Endocrine, Metabolic, Genetic
9.1.7.1. Market Revenue and Forecast (2020-2032)
9.1.8. Immunology & Inflammation
9.1.8.1. Market Revenue and Forecast (2020-2032)
9.1.9. Ophthalmology
9.1.9.1. Market Revenue and Forecast (2020-2032)
9.1.10. Hematology
9.1.10.1. Market Revenue and Forecast (2020-2032)
9.1.11. Gastroenterology
9.1.11.1. Market Revenue and Forecast (2020-2032)
9.1.12. Others
9.1.12.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Cell and Gene Therapy Clinical Trials Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Phase (2020-2032)
10.1.2. Market Revenue and Forecast, by Indication (2020-2032)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Phase (2020-2032)
10.1.3.2. Market Revenue and Forecast, by Indication (2020-2032)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Phase (2020-2032)
10.1.4.2. Market Revenue and Forecast, by Indication (2020-2032)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Phase (2020-2032)
10.2.2. Market Revenue and Forecast, by Indication (2020-2032)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Phase (2020-2032)
10.2.3.2. Market Revenue and Forecast, by Indication (2020-2032)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Phase (2020-2032)
10.2.4.2. Market Revenue and Forecast, by Indication (2020-2032)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Phase (2020-2032)
10.2.5.2. Market Revenue and Forecast, by Indication (2020-2032)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Phase (2020-2032)
10.2.6.2. Market Revenue and Forecast, by Indication (2020-2032)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Phase (2020-2032)
10.3.2. Market Revenue and Forecast, by Indication (2020-2032)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Phase (2020-2032)
10.3.3.2. Market Revenue and Forecast, by Indication (2020-2032)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Phase (2020-2032)
10.3.4.2. Market Revenue and Forecast, by Indication (2020-2032)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Phase (2020-2032)
10.3.5.2. Market Revenue and Forecast, by Indication (2020-2032)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Phase (2020-2032)
10.3.6.2. Market Revenue and Forecast, by Indication (2020-2032)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Phase (2020-2032)
10.4.2. Market Revenue and Forecast, by Indication (2020-2032)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Phase (2020-2032)
10.4.3.2. Market Revenue and Forecast, by Indication (2020-2032)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Phase (2020-2032)
10.4.4.2. Market Revenue and Forecast, by Indication (2020-2032)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Phase (2020-2032)
10.4.5.2. Market Revenue and Forecast, by Indication (2020-2032)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Phase (2020-2032)
10.4.6.2. Market Revenue and Forecast, by Indication (2020-2032)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Phase (2020-2032)
10.5.2. Market Revenue and Forecast, by Indication (2020-2032)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Phase (2020-2032)
10.5.3.2. Market Revenue and Forecast, by Indication (2020-2032)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Phase (2020-2032)
10.5.4.2. Market Revenue and Forecast, by Indication (2020-2032)
Chapter 11. Company Profiles
11.1. IQVIA
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. ICON Plc
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Laboratory Corporation of America Holdings
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Charles River Laboratories International, Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. PAREXEL International Corp.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Syneos Health
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Medpace Holdings, Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. PPD Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Novotech
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Veristat, LLC
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Why should you invest in this report?
If you are aiming to enter the global cell and gene therapy clinical trials market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for cell and gene therapy clinical trials are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2023-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
